Navigation Links
Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
Date:6/5/2009

RECORD trial also demonstrates durable blood sugar control over time with Avandia

LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 5 /PRNewswire/ -- Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.

Results from the 4,447-patient Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study, which was sponsored by GlaxoSmithKline, Avandia's maker, were also published online today in the medical journal The Lancet.

RECORD is a large, prospective, randomized, controlled study that was initiated in 2001, and designed to compare cardiovascular outcomes of patients on Avandia added to metformin or sulfonylurea to those on metformin and sulfonylurea. The study confirmed its primary hypothesis. It showed that cardiovascular hospitalization or cardiovascular death (which includes heart attack, congestive heart failure, and stroke) was not statistically different between the two groups after an average of 5.5 years of therapy. This translates into 321 events (14.5 percent) among patients receiving Avandia compared to 323 events (also 14.5 percent) for patients receiving control medications (hazard ratio=0.99, 95% confidence interval=0.85 to 1.16) (Data on the individual components are provided below.)

"RECORD provides a robust assessment of rosiglitazone's cardiovascular safety and achieving the study's primary endpoint leads us to conclude that rosiglitazone carries no increased risk of overall cardiovascular death or hospitalization compared to the most commonly used diabetes medicines, metformin and sulfonylurea, which have been used for decades," said Dr. Philip D. Home, chairman of the RECORD Steering Committ
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
2. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
3. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
4. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
5. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
6. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
7. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
8. Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
9. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
10. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
11. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ewswire-FirstCall/--HeskaCorporation(HSKA);("Heska...ltyproductstotheveterinaryindustry,announcedtodaya...lyofbloodgasproductsandaffiliatedconsumablesforthe...com/cgi-bin/prnh/20000622/HESKALOGO ) ,, "Heska...ofadvancedpoint-of-carediagnostics,"commentedMicha...
(Date:11/25/2009)...re/--BioTrendsResearchGroup,Inc.releasedWave1ofits...multi-phasesyndicatedmarketresearchprojecttracking...uctlaunchthroughthefirstsixmonthsofavailability.Ea...om75uniqueDermatologistsandqualitativeinformationf...a,obstaclestouse,typicalpatienttypes,productpercep...
(Date:11/25/2009)...PRNewswire/--RegadoBiosciences,aprivatelyheldcompa...hactivecontrolagents,announcedthatDavidMazzo,PhD,C...stAnnualHealthCareConferenceattheNewYorkPalaceHote...1:10pm(EST)onTuesday,December1andwillincludeanover...elopmentprogram,theanticoagulantsystem,REG1.Thehea...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Graffinity Enters into Drug Discovery Research Collaboration with Genentech 10370 1Graffinity Enters into Drug Discovery Research Collaboration with Genentech 10370 2Scientists remove amyloid plaques from brains of live animals with Alzheimers disease 10367 1Scientists remove amyloid plaques from brains of live animals with Alzheimers disease 10367 2Stemedica Completes Meeting with the FDA 14477 1Stemedica Completes Meeting with the FDA 14477 2Stemedica Completes Meeting with the FDA 14477 3
...and, May 9 An emergency,veterinary team from the ...,is on stand-by in Thailand awaiting authority to ...lieve the suffering of thousands of animals,that h...hoods., WSPA is receiving daily updates from The ...tions (FAO) while preparing its Rapid,Assessment a...
... The risk of the two major,prostate diseases, can...,reduced by changes in lifestyle, such as avoiding... healthy diet. Alan Kristal, Dr.P.H., associate,he...nson Cancer Research,Center in Seattle, has conduc...lpless against prostate cancer or BPH., For examp...
Other Medicine Technology:Animals That Cyclone Survivors Depend on Need Help Now 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4
(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanetW...tionandResearch,titled"ADifficultBalance-PainManag...9issueofTheNewEnglandJournalofMedicine. ,, (Log...ALOGO ) ,, Inthearticle,WoodcockdiscussesFDAeff...orthosewhoneeditandmanagingtherisksposedbyvariousa...
(Date:11/25/2009)...Endorsements,Business,andPressJoinEfforttoEducate ...--Onceagain,theNationalBipolarFoundationandtheMedi..."Safe,tilStable"program,whichisnowbeingwidelyaccep...r.Today,theNationalBipolarFoundationreceivedaprocl...romtheLt.GovernorofLouisianaMitchLandrieu.TheNatio...
(Date:11/25/2009)...ery that grew out of a collaboration between UCLA ...ope to the nearly 10 million Americans who suffer ...wn as hardening of the arteries, peripheral arteri...m in which narrowed arteries reduce blood flow to ...for vascular disease, heart attack and stroke, and...
(Date:11/25/2009)... to fight rheumatoid arthritis, could help newly d...ESDAY, Nov. 25 (HealthDay News) -- A drug commonly...id arthritis now also shows some promise in helpin..., The drug, rituximab (Rituxan), helped patients...ough the disease had destroyed some of their pancr...
(Date:11/25/2009)... by neurological symptoms, study finds , ...gical side effects are among the potential problem...r who were treated with cisplatin-based chemothera... 1,409 Norwegian men treated for unilateral testic... a follow-up survey conducted from 1998 to 2002. ,...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
... by the researchers now reckons the evil effects o... protects against the development of brain tumors ...s done a couple of years ago , an unexpected findi...// The recent study undwells the fact that g...
...al engineering team has announced the development ... person,with an ability to deliver a visual acuity...ature television camera and an ultrasonic distance... processing the video and distance signals,// the ...
...ng history of sorts, doctors in Ohio, the United S...ar vein to a man to rid him of a painful ulcer due...his is the first time a bovine vein is used in man...ceeded very well. Dr. Hugh Beebe, the center's dir...
...chers at the Georgetown University Lombardi cancer...a protein that they say, is responsible for the sp...lled Pa 28 alpha, can also cause the spread of oth... To isolate the protein, Ngaiza and colleagues ...
...test in cardiology is OCT, which expands into Opti...de many cardiologists sit up and take notice and i...oped by Dr. Brett Bouma an assistant professor at ...ound and will allow cardiologists to view the stat...
...reakthrough using gene therapy mouthwash promises ...hwash wards off oral cancer by destroying suspicio...nt. The idea is to attack the pre-cancerous patche...nthusiastic, as the patches have disappeared compl...
Other Medicine News:Health News:Fight oral cancer with gene therapy mouthwash, 2
CROSSER™ 14 Coronary CTO Recanilazation System
...ial control assayed for all parameters on the Coul...ff/AcT diff2, MD Series and ONYX Series; Abbott CE...s 60; and Diatron Abacus and Abacus Junior. Para 1... a six-month closed-vial stability and is availabl...
...ential control that controls all parameters, inclu... 750/LH 755, MAXM and HmX instruments. The assay c...or all three levels. White blood cell types and re...lly significant ranges. This unique product has 14...
...ogy control, offers complete assay values for the ...he Coulter GENS, STKS, MAXM and HmX. This unique p...sed-vial stability and is available in low, normal... compatible with all cassette systems. Barcoded vi...
Medicine Products: